Arcus Biosciences, Inc. (NYSE:RCUS) Receives $39.75 Consensus Target Price from Analysts

Shares of Arcus Biosciences, Inc. (NYSE:RCUS) have received a consensus recommendation of “Moderate Buy” from the nine research firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $38.11.

A number of research analysts have recently issued reports on RCUS shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcus Biosciences in a research report on Friday, July 5th. Barclays cut their price objective on shares of Arcus Biosciences from $35.00 to $25.00 and set an “overweight” rating on the stock in a research report on Monday. Citigroup lifted their price objective on shares of Arcus Biosciences from $36.00 to $38.00 and gave the stock a “buy” rating in a research report on Monday, June 3rd. Wedbush reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of Arcus Biosciences in a research report on Thursday, May 9th. Finally, Truist Financial lowered their target price on shares of Arcus Biosciences from $50.00 to $44.00 and set a “buy” rating for the company in a research note on Monday, June 24th.

Institutional Trading of Arcus Biosciences

Several large investors have recently made changes to their positions in RCUS. Decheng Capital LLC purchased a new stake in shares of Arcus Biosciences in the 4th quarter valued at $16,613,000. Vanguard Group Inc. boosted its holdings in Arcus Biosciences by 4.2% during the fourth quarter. Vanguard Group Inc. now owns 4,680,716 shares of the company’s stock worth $89,402,000 after buying an additional 186,898 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Arcus Biosciences by 11.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,594,609 shares of the company’s stock worth $30,459,000 after buying an additional 158,094 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in Arcus Biosciences by 26.9% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 685,025 shares of the company’s stock worth $12,933,000 after buying an additional 145,298 shares in the last quarter. Finally, Panagora Asset Management Inc. boosted its holdings in Arcus Biosciences by 130.6% during the fourth quarter. Panagora Asset Management Inc. now owns 228,996 shares of the company’s stock worth $4,374,000 after buying an additional 129,697 shares in the last quarter. 92.89% of the stock is owned by hedge funds and other institutional investors.

Arcus Biosciences Price Performance

NYSE RCUS opened at $14.09 on Friday. The company’s 50-day simple moving average is $15.86 and its two-hundred day simple moving average is $16.70. Arcus Biosciences has a one year low of $12.95 and a one year high of $25.47.

Arcus Biosciences (NYSE:RCUS) last posted its earnings results on Wednesday, May 8th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.92. Arcus Biosciences had a negative net margin of 97.47% and a negative return on equity of 40.98%. The business had revenue of $145.00 million for the quarter, compared to the consensus estimate of $28.77 million. During the same quarter last year, the firm posted ($1.09) EPS. The company’s revenue for the quarter was up 480.0% on a year-over-year basis. Analysts predict that Arcus Biosciences will post -2.61 earnings per share for the current year.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.